Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03506347 · ClinicalTrials.gov registry record · Phase 2
Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03506347: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03506347 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03506347, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether or not giving a lower dose of antibiotics (Vancomycin) in the area where it is needed (the knee joint) is more effective at obtaining adequate tissue levels of the antibiotic than the current standard dose which is given intravenously (IV) through a wrist vein. The use of intraosseous regional administration (IORA) of vancomycin requires the use of a tourniquet for the duration of the procedure. Many surgeons prefer to perform the surgery with tourniquet use minimised or without a tourniquet at all. The aim of this study is to evaluate whether IORA vancomycin can achieve effective tissue concentrations with tourniquet use minimised.
Interventions
- DRUG Vancomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2019-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03506347
The ClinicalTrials.gov registry entry for NCT03506347 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vancomycin is the first listed.
NCT03506347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03506347 about?
NCT03506347 is a clinical study titled "Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement". The purpose of this study is to determine whether or not giving a lower dose of antibiotics (Vancomycin) in the area where it is needed (the knee joint) is more effective at obtaining adequate tissue levels of the antibiotic than the current standard dose which is given intravenously (IV) through a ...
What is the current status of trial NCT03506347?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2018-09-24. Estimated completion is 2019-01-17.
What interventions are being tested in trial NCT03506347?
The interventions under investigation include: Vancomycin (DRUG).
Who is sponsoring clinical trial NCT03506347?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.